US 10,240,208 B2 · MicroRNA assay for detection and management of pancreatic cancer precursors

Abstract

The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion. Microarray containing miRNAs indicative of the presence of pancreatic cancer, or having a high risk of pancreatic cancer development, particularly, in a subject having a pancreatic lesion, and methods of use of the microarrays are also provided.

Claims10

Dependent claims

A method of treating an intraductal papillary mucinous neoplasm (IPMN), and/or delaying onset of the development of, pancreatic cancer in a subject having an IPMN, the method comprising:

(a) detecting the level of expression of one or more miRNAs in a blood sample from the subject, wherein the one or more miRNAs are selected from among miR-200a-3p, miR-1185-5p, miR-33a-5p, miR-574-3p, and miR-663b;
(b) comparing the detected expression level to a reference expression level, wherein a differential expression of the one or more miRNAs in the blood sample, as compared to the reference expression level, is indicative of the presence of a malignant IPMN, or a higher risk of developing pancreatic cancer, versus a benign IPMN, or a lower risk of developing pancreatic cancer, respectively;
and
(c) administering a therapy to treat the IPMN and/or delay onset of the pancreatic cancer to the subject identified as having the malignant IPMN, or at a higher risk of developing pancreatic cancer, wherein the therapy comprises surgical resection, pancreatoduodenectomy (Whipple procedure), chemotherapy, radiation, immunotherapy, or a combination of two or more of the foregoing.

1 more element

Dependencies are inferred from the claim text.

MicroRNA assay for detection and management of pancreatic cancer precursors

Life of this patent

MicroRNA assay for detection and management of pancreatic cancer precursors

Life of this patent

Abstract

Claims10